Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.3518 |
---|---|
High | 0.354 |
Low | 0.34 |
Bid | 0.345 |
Offer | 0.363 |
Previous close | 0.355 |
Average volume | 6.29k |
---|---|
Shares outstanding | 180.73m |
Free float | 168.42m |
P/E (TTM) | -- |
Market cap | 70.19m USD |
EPS (TTM) | -0.2443 USD |
Data delayed at least 15 minutes, as of Oct 08 2024.
More ▼
Press releases
- Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
- Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update
- Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
- Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments
- Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
- Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
More ▼